Libtayo® (cemiplimab) Approved by the European Commission for First-Line Treatment of Patients with Advanced Non-small Cell Lung Cancer with ≥50% PD-L1 Expression

  • Israel Lowy,

Press/Media

Period25 Jun 2021 → 26 Jun 2021

Media coverage

17

Media coverage